IBDEI1NG ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27600,1,4,0)
 ;;=4^C92.61
 ;;^UTILITY(U,$J,358.3,27600,2)
 ;;=^5001808
 ;;^UTILITY(U,$J,358.3,27601,0)
 ;;=C92.60^^132^1320^10
 ;;^UTILITY(U,$J,358.3,27601,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27601,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
 ;;^UTILITY(U,$J,358.3,27601,1,4,0)
 ;;=4^C92.60
 ;;^UTILITY(U,$J,358.3,27601,2)
 ;;=^5001807
 ;;^UTILITY(U,$J,358.3,27602,0)
 ;;=C92.A1^^132^1320^11
 ;;^UTILITY(U,$J,358.3,27602,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27602,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
 ;;^UTILITY(U,$J,358.3,27602,1,4,0)
 ;;=4^C92.A1
 ;;^UTILITY(U,$J,358.3,27602,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,27603,0)
 ;;=C92.A0^^132^1320^12
 ;;^UTILITY(U,$J,358.3,27603,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27603,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,27603,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,27603,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,27604,0)
 ;;=C92.51^^132^1320^13
 ;;^UTILITY(U,$J,358.3,27604,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27604,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,27604,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,27604,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,27605,0)
 ;;=C92.50^^132^1320^14
 ;;^UTILITY(U,$J,358.3,27605,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27605,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,27605,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,27605,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,27606,0)
 ;;=C94.40^^132^1320^17
 ;;^UTILITY(U,$J,358.3,27606,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27606,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,27606,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,27606,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,27607,0)
 ;;=C94.42^^132^1320^15
 ;;^UTILITY(U,$J,358.3,27607,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27607,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,27607,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,27607,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,27608,0)
 ;;=C94.41^^132^1320^16
 ;;^UTILITY(U,$J,358.3,27608,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27608,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,27608,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,27608,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,27609,0)
 ;;=D62.^^132^1320^18
 ;;^UTILITY(U,$J,358.3,27609,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27609,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,27609,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,27609,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,27610,0)
 ;;=C92.41^^132^1320^19
 ;;^UTILITY(U,$J,358.3,27610,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27610,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,27610,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,27610,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,27611,0)
 ;;=C92.40^^132^1320^20
 ;;^UTILITY(U,$J,358.3,27611,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27611,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,27611,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,27611,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,27612,0)
 ;;=D56.0^^132^1320^21
 ;;^UTILITY(U,$J,358.3,27612,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27612,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,27612,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,27612,2)
 ;;=^340494
